Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Myeloproliferative Neoplasm Subjects

NCT04041050 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04041050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04041050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Myeloproliferative Neoplasm Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 8, 2019
Completion date
December 31, 2026
Enrollment
85 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasm